ATE293691T1 - Myostatin genpromoter und inhibierung dessen aktivierung - Google Patents

Myostatin genpromoter und inhibierung dessen aktivierung

Info

Publication number
ATE293691T1
ATE293691T1 AT00941296T AT00941296T ATE293691T1 AT E293691 T1 ATE293691 T1 AT E293691T1 AT 00941296 T AT00941296 T AT 00941296T AT 00941296 T AT00941296 T AT 00941296T AT E293691 T1 ATE293691 T1 AT E293691T1
Authority
AT
Austria
Prior art keywords
inhibition
activation
myostatin
gene promoter
myostatin gene
Prior art date
Application number
AT00941296T
Other languages
English (en)
Inventor
Jinshyun R Wu-Wong
Jiahong Wang
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE293691T1 publication Critical patent/ATE293691T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00941296T 1999-06-10 2000-06-09 Myostatin genpromoter und inhibierung dessen aktivierung ATE293691T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/329,685 US6284882B1 (en) 1999-06-10 1999-06-10 Myostatin gene promoter and inhibition of activation thereof
PCT/US2000/015868 WO2000077206A2 (en) 1999-06-10 2000-06-09 The myostatin gene promoter and inhibition of activation thereof

Publications (1)

Publication Number Publication Date
ATE293691T1 true ATE293691T1 (de) 2005-05-15

Family

ID=23286552

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941296T ATE293691T1 (de) 1999-06-10 2000-06-09 Myostatin genpromoter und inhibierung dessen aktivierung

Country Status (10)

Country Link
US (2) US6284882B1 (de)
EP (1) EP1185649B1 (de)
JP (1) JP4625602B2 (de)
AT (1) ATE293691T1 (de)
CA (1) CA2375820C (de)
DE (1) DE60019586T2 (de)
ES (1) ES2240108T3 (de)
MX (1) MXPA01012665A (de)
PT (1) PT1185649E (de)
WO (1) WO2000077206A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878552A1 (de) 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molekularer Nachweis von chromosomalen Veränderungen
JP2002513587A (ja) 1998-05-04 2002-05-14 ダコ エー エス 染色体異常を検出するための方法およびプローブ
ES2318900T3 (es) * 1998-07-15 2009-05-01 Metamorphix, Inc. Promotor del factor de diferenciacion del crecimiento y sus usos.
US6617440B1 (en) * 1999-07-30 2003-09-09 Pfizer, Inc. Myostatin regulatory region, nucleotide sequence determination and methods for its use
CA2453189A1 (en) * 2001-07-11 2003-01-23 Ovita Limited Bioassay for myostatin
CN101287484B (zh) * 2002-12-20 2012-10-10 安姆根有限公司 抑制肌肉生长抑制素的结合剂
US8460864B2 (en) * 2003-01-21 2013-06-11 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US9068234B2 (en) * 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US8426194B2 (en) * 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
CA2551877A1 (en) * 2003-12-31 2005-07-21 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
NZ554824A (en) 2004-10-22 2010-10-29 Revivicor Inc Porcines that lack endogenous antibody chains and express exogenous immunoglobulins
JP2008526201A (ja) 2004-12-30 2008-07-24 シェーリング−プラウ・リミテッド 中和エピトープベースの成長増強ワクチン
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
CA2601667A1 (en) * 2005-03-23 2006-09-28 Wyeth Detection of gdf-8 modulating agents
AU2006232914A1 (en) * 2005-03-23 2006-10-12 Wyeth Detection of an immune response to GDF-8 modulating agents
CA2538208A1 (en) * 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
JP2009518422A (ja) * 2005-12-06 2009-05-07 アムジェン インコーポレイテッド ミオスタチン・アンタゴニストの使用
US8426374B1 (en) 2006-05-04 2013-04-23 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Method for modifying myostatin expression
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
EP2348827B1 (de) 2008-10-27 2015-07-01 Revivicor, Inc. Immunsupprimierte huftiere
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
EP3858993A1 (de) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von duchenne-muskeldystrophie und damit assoziierten erkrankungen
WO2025110681A1 (ko) * 2023-11-20 2025-05-30 ㈜라트바이오 신규 프로모터

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
DK0690873T3 (da) * 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
WO1998033887A1 (en) * 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
ES2318900T3 (es) * 1998-07-15 2009-05-01 Metamorphix, Inc. Promotor del factor de diferenciacion del crecimiento y sus usos.
US6617440B1 (en) 1999-07-30 2003-09-09 Pfizer, Inc. Myostatin regulatory region, nucleotide sequence determination and methods for its use

Also Published As

Publication number Publication date
CA2375820C (en) 2010-07-27
MXPA01012665A (es) 2002-07-22
US6284882B1 (en) 2001-09-04
PT1185649E (pt) 2005-08-31
CA2375820A1 (en) 2000-12-21
US20010049435A1 (en) 2001-12-06
JP4625602B2 (ja) 2011-02-02
US6399312B2 (en) 2002-06-04
DE60019586D1 (de) 2005-05-25
DE60019586T2 (de) 2006-03-09
JP2003528574A (ja) 2003-09-30
WO2000077206A3 (en) 2001-12-06
ES2240108T3 (es) 2005-10-16
WO2000077206A2 (en) 2000-12-21
EP1185649B1 (de) 2005-04-20
EP1185649A2 (de) 2002-03-13

Similar Documents

Publication Publication Date Title
DE60019586D1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
AU3652102A (en) Compounds and their uses
BG106585A (en) Kinase inhibitors as therapeutic agents
PT966465E (pt) Inibidores do enzima imfdh
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
PE20020521A1 (es) Compuestos heterociclicos sustituidos para tratar la resistencia a multiples drogas
MY134783A (en) Rho-kinase inhibitors
MY142915A (en) Rho-kinase inhibitors
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
GEP20084488B (en) Use of therapeutic agents for treating pain
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
DE60324544D1 (de) Muskarin antagonisten
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
EP1244452A4 (de) Urotensin-ii rezeptorantagonisten
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
ATE443044T1 (de) Tace inhibitoren
TR200102448T2 (tr) COPD tedavisi için kontrollu salma formülasyonu.
BG105710A (en) 5ht1 antagonists for antidepressant therapy
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
EA200100930A1 (ru) Способ лечения хозл
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
WO2004060878A3 (en) Inhibitors of phosphatases
WO2004078180A3 (en) Naaladase inhibitors for treating opioid tolerance

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1185649

Country of ref document: EP

REN Ceased due to non-payment of the annual fee